

3 August 2018

Our Ref: RFI 24155

Dear

**Freedom of Information Act 2000
Information in relation to Non-Small Cell Lung Cancer**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 6 July 2018.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Victoria Smith
Information Governance Assistant

RFI 24155

Appendix A

Q1. Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive.

A1. Please see Table 1 below.

Table 1

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Patients with NSCLC Stage IIIB/IV (Stage 3b/4)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

Q2. Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months April 2018 to June 2018 inclusive, with the following therapies.

A2. Please see Table 2 below. You will note that the numbers have been masked in Table 2 and this is due to small numbers within a small geographical area.

Table 2

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Docetaxel (mono or combination therapy)	<10	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Nivolumab (Opdivo)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	